BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a KRAS G12C inhibitor for antitumor; BEBT-808, an oral small molecule GLP-1R full agonist for metabolic disease; BEBT-809, a GPR75 pathway inhibitor for metabolic disease; and BEBT-508, a small nucleic acid drug. The company was founded in 2012 and is based in Guangzhou, China.
तुलना करने के लिए मीट्रिक्स | 688759 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध688759पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | - | 14.3x | −0.5x | |
PEG अनुपात | - | −0.13 | 0.00 | |
क़ीमत/बुक | - | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.7x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | −41.6% | 45.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | −15.8% | 4.9% | अनलॉक करें |